Biogen Acquires Apellis for $5.6B
Biogen acquired Apellis in May 2026 to expand Biogen’s presence in immunology and rare diseases.
Beam Therapeutics Enters into $500 Million Financing Agreement with Investment Firm Sixth Street
Beam will use the funding to further develop risto-cel.
Penn Vet Researchers Invent Skin‑targeted Dual mRNA Vaccine Platform to Deliver Long‑lasting Protection Against Cutaneous Leishmaniasis
This experimental vaccine uses mRNA technology to train immune cells to recognize the parasite that causes cutaneous.
Penn Faculty Weighs in On the Future of American Science
John Wherry, PhD, the Richard and Barbara Schiffrin President's Distinguished Professor at Penn Medicine, explains how decades of federal funding for basic science enabled breakthroughs.
CAR T Cell Therapy for Lymphoma Leads to 10 Year Remissions for Patients
The follow-up study of patients ten years later showed promising results.
ARPA-H Awards $43 million to Philadelphia Gene Therapy Researchers to Advance Rare Disease Treatments
Learn more about the recipients.
Network Bio Launches with $50 million in Funding to Create a Research Network of Large Biobanks to Drive AI Medical Research
Several U.S. Academic Medical Centers, including Penn Medicine, have partnered with Network Bio to generate large-scale multi-omic and multi-modal datasets.
Dispatch Bio Initiates Clinical Trials for a New Type of Cancer Treatment
The technology is intended to overcome a key limitation of current CAR-T cell therapies by broadening the range of tumors that can be targeted and treated.
Biogen Reports Early Success from Apellis Acquisition
Since Biogen’s acquisition of Apellis in May 2026, the company’s C3 complement therapies, Syfovre® and Empaveli®, have generated a combined $128 million in revenues.
Kira Pharmaceuticals to Merge with Jasper Therapeutics in a Deal Backed by $132M to Advance Immune Disease Pipeline
Jasper Therapeutics recently completed its merger with Kira Pharmaceuticals.